# Intuitive Surgical Inc. (ISRG)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ISRG/primer

## Business Model

---
ticker: ISRG
step: 01
generated: 2026-05-12
source: quick-research
---

### Intuitive Surgical, Inc. (ISRG) — Business Overview

#### Business Description
Intuitive Surgical is the global leader in robotic-assisted surgery (RAS), with a dominant installed base of 11,395+ da Vinci surgical systems performing 3M+ surgical procedures annually. The company is mid-rollout of da Vinci 5 (next-gen flagship platform) and rapidly scaling Ion (bronchoscopy/lung biopsy) and SP (single-port surgery). After 20+ years of effectively no soft-tissue robotic competition, Medtronic Hugo and CMR Versius now FDA-cleared in US — first serious competitive threat ever.

#### Revenue Model
- **Instruments & Accessories (~57% of revenue, recurring):** Consumables sold per-procedure ("razor-and-blade" model)
- **Systems (~26%):** da Vinci 5, Xi, X, SP, Ion — large capital purchases by hospitals
- **Services (~17%):** Annual service contracts on installed base
- ~74% recurring revenue (Instruments + Services) — exceptional for medical device company

#### Products & Services

##### Surgical Robots
- **da Vinci 5:** Next-gen flagship launched 2024; Force Feedback haptics; 232 placements in Q1 2026 alone (up from 147)
- **da Vinci Xi/X:** Predecessors still in widespread use; being replaced via trade-in upgrade program
- **da Vinci SP:** Single-port for tight anatomy (urology, head & neck)
- **Ion:** Robotic bronchoscopy for lung biopsy — 325K+ procedures cumulative; ~1,000 system installed base
- **da Vinci 5 Cardiac (FDA cleared 2026):** Expansion into cardiac procedures

##### Instruments & Accessories
- Per-procedure consumables — EndoWrist instruments, energy devices, vision system components
- Sold to hospitals at high gross margin; ~$2,000-3,000 per procedure
- Faces emerging competition from remanufactured / third-party instruments

##### Services
- Annual service contracts on installed base
- Software updates, AI-enabled feature releases
- Training programs

#### Customer Base & Go-to-Market
- **Hospitals:** ~11,395 da Vinci system installed base (US ~6,200; International ~5,200)
- **Surgeons:** Trained on da Vinci platform (~60,000+ surgeon-users globally)
- **Patients:** 3.15M procedures performed in 2025
- **Procedures by specialty:** Urology (prostatectomy), General surgery (cholecystectomy, hernia, bariatric), Gynecology (hysterectomy), Cardiothoracic (newly cleared), Head & Neck, Colorectal
- **Geographic mix:** ~70% US, ~30% International (US growing faster than International recently due to da Vinci 5 launch)

#### Competitive Position
Intuitive Surgical has the closest thing to a "moat" in medical devices: (1) 11,395+ installed base = enormous trained surgeon network with switching costs, (2) clinical evidence — 30,000+ peer-reviewed publications since 2000, (3) razor-and-blade economics with ~74% recurring revenue, (4) AI/data scale from millions of procedures recorded. New competitors (Medtronic Hugo, CMR Versius Plus, Stryker Mako for ortho, J&J Ottava) face the chicken-and-egg problem of needing surgical training programs + clinical evidence to challenge da Vinci.

#### Key Facts
- Founded: 1995 (Frederic Moll, Robert Younge, John Freund)
- Headquarters: Sunnyvale, CA
- Employees: ~13,000
- Exchange: NASDAQ
- Sector / Industry: Health Care / Health Care Equipment
- Market Cap: ~$220B (May 2026)
- CEO: Gary Guthart, Ph.D. (since 2010)
- Dividend: None — focuses capital on R&D + buybacks
- da Vinci installed base growth: +12% YoY (Q1 2026 vs Q1 2025)
- 2026 da Vinci procedure guidance: 13.5-15.5% growth

## Financial Snapshot

---
ticker: ISRG
step: 04
generated: 2026-05-12
source: quick-research
---

### Intuitive Surgical, Inc. (ISRG) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $7.12B | $8.35B | $10.07B | +21% |
| Procedure Volume Growth | +21% | +17% | +18% | |
| Non-GAAP Gross Margin | 69.5% | 69.1% | 67-67.5% | -150bps (tariff impact) |
| Non-GAAP Operating Margin | 31% | 35% | 38% | +300bps |
| Non-GAAP Net Income | $1.96B | $2.50B | $3.40B | +36% |
| Non-GAAP EPS (diluted) | $5.45 | $7.05 | $9.50 | +35% |

#### Q1 2026 Highlights

| Metric | Q1 2026 | YoY |
|--------|---------|-----|
| Revenue | $2.77B | +23% |
| Procedures | 847K | +16% YoY |
| Ion Procedures | 43K | +39% YoY |
| da Vinci 5 placements (Q1) | 232 systems | +58% vs 147 prior year |
| EBIT growth | +40% YoY | |

#### Installed Base & Placements

| Metric | Value |
|--------|-------|
| da Vinci installed base (Q1 2026) | 11,395 (+12% YoY) |
| da Vinci installed base (YE 2025) | 11,106 |
| da Vinci 5 placements (FY2025) | 870 (vs 362 FY24) |
| Total da Vinci placements FY25 | 1,721 |
| Procedures FY2025 | 3.15M (+18%) |
| Ion installed base | ~1,000 systems |
| Ion procedures cumulative | 325K+ |

#### 2026 Guidance (raised in Q1)

| Metric | 2026 Guide |
|--------|------------|
| da Vinci Procedure Growth | 13.5-15.5% (raised from earlier guide) |
| Tariff Revenue Impact | ~1% headwind |
| Non-GAAP Gross Margin | 67-67.5% (vs 69.1% FY24) |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$3.5B |
| Capital Expenditures | ~$0.8B |
| Free Cash Flow | ~$2.7B |
| Cash & Investments | ~$9B |
| Total Debt | ~$0B (debt-free) |
| Net Cash Position | ~$9B |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~43x | EV/Sales: ~22x | FCF Yield: ~1.2%
- Net Cash: ~$9B
- Recurring Revenue %: ~74% (Instruments + Services)

#### Growth Profile
ISRG is in a multi-year sustained growth phase: FY25 revenue +21%, procedures +18%. da Vinci 5 adoption accelerating (870 placements 2025 vs 362 2024 — 2.4x). Q1 2026 EBIT +40%. Force Feedback haptics rolling out. Cardiac procedures newly FDA-cleared on da Vinci 5. Tariff drag (-100bps gross margin) is the main near-term headwind.

#### Forward Estimates
- **FY2026E Revenue:** ~$11.5-11.8B (+15-17%)
- **FY2026E EPS:** ~$10.50 (+11%)
- **FY2027E Revenue:** ~$13.5B (+17%)
- **FY2027E EPS:** ~$12.50 (+20%)

#### Capital Return
- No dividend
- Buybacks: ~$0.5-1B annual modest pace
- Net cash $9B provides flexibility for M&A or accelerated buybacks
- TIKR / Citi: $700+ price targets imply ~$220B+ market cap on continued growth

## Recent Catalysts

---
ticker: ISRG
step: 12
generated: 2026-05-12
source: quick-research
---

### Intuitive Surgical, Inc. (ISRG) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **da Vinci 5 in early innings of multi-year cycle** — Placements jumped from 147 (Q1 2025) → 232 (Q1 2026), with full-year placements +140% (870 in 2025 vs 362 in 2024). da Vinci 5 has ~11% higher utilization vs predecessor. Trade-in cycle for ~6,000+ Xi/X systems represents multi-year tailwind. Force Feedback haptics is a clinically meaningful innovation that competitors lack.

2. **Procedure growth 13.5-15.5% durable** — 2026 guidance for da Vinci procedure growth 13.5-15.5%, raised intra-year. RAS penetration remains low — global penetration in target procedures still <30%, with US >40% in mature segments (urology, gyn) but International expansion accelerating. Cardiac procedures newly FDA-cleared on da Vinci 5 opens $5-10B incremental market.

3. **Strongest moat in medical devices** — 11,395+ installed systems = enormous trained surgeon base with switching costs measured in years of retraining. 30,000+ peer-reviewed publications since 2000. 74% recurring revenue. Net cash $9B. Competitors face chicken-and-egg of needing clinical evidence + trained surgeon network — moat compounds.

4. **40% EBIT growth in Q1 2026** — Despite tariff drag, operating leverage strong: EBIT +40% YoY in Q1 2026. Long-term operating margin trajectory toward 40%+ as revenue scales and tariff impact fades. Combined with 13-15% revenue growth, EPS could compound at 18-25% for multiple years.

#### Bear Case Risks

1. **43x forward P/E — premium valuation** — ISRG trades at ~43x forward EPS vs healthcare sector average ~17x. While quality and growth justify a premium, this is one of the most expensive large-cap medical devices. Any procedure growth slip below 13% or hospital capex slowdown could trigger meaningful multiple compression.

2. **First serious competition in 20+ years** — Medtronic Hugo and CMR Versius Plus now FDA-cleared in US for soft-tissue surgery — first credible direct competitors to da Vinci ever. While moat is strong, even small share losses on the margin could compress placements + margins. Stryker (Mako) ortho, J&J (Ottava planned), Smith+Nephew (CORI) round out competition.

3. **Tariff drag + margin compression** — 2026 guidance includes ~1% revenue tariff impact and 100bps gross margin compression. Combined with rising R&D for new platforms (da Vinci 5 generation, AI features, Surgical Robotics Foundation Model), near-term margin pressure may not fully reverse until 2027.

4. **Pricing pressure on instruments + accessories** — The high-margin "razor-and-blades" segment (~57% of revenue) faces pricing pressure as third parties push remanufactured alternatives. If hospitals successfully push through reusing/remanufacturing more instruments, the recurring revenue economics could deteriorate.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Procedure growth + da Vinci 5 placement trajectory; tariff offset progress
- **Q3 2026 earnings (October 2026)** — Cardiac procedure launch metrics
- **da Vinci 5 expansion to additional specialties** — Cardiac done; thoracic + others in pipeline
- **Force Feedback rollout** — Expanding availability throughout 2026
- **Competitive launches** — Medtronic Hugo + CMR Versius placement wins/losses

#### Analyst Sentiment

Sell-side consensus is **Buy** with Citi recently upgraded to Buy. Average price targets in the $620-720 range vs. recent ~$580 trading levels. TIKR sees $700+ targets justified. Bulls cite procedure growth, da Vinci 5 momentum, and "closest thing to a forever stock." Bears focus on 43x valuation and emerging competition. Consensus skews bullish — but valuation premium is the persistent debate.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/isrg
- Full research API: GET /api/v1/research/ISRG/memo
- Coverage universe: /stocks